Current therapies used in the treatment of breast cancer are limited by systemic toxicity, rapid drug metabolism and intrinsic and acquired drug resistance. We have previously shown that adenoviral-mediated transfer of the melanoma differentiation-associated gene-7 (mda-7) elicits growth inhibition and apoptosis in various tumor types. Here, we evaluate the effects of Ad-mda7, alone and in combination with other therapies, against a panel of nine breast tumor cell lines and their normal counterparts; we report selective Ad-mda7-mediated p53-independent growth inhibition, G2/M cell cycle arrest, and apoptosis. In vivo, Ad-mda7 induced p53-independent tumor growth inhibition (Po0.004) in multiple xenograft models. We then evaluated the combination of Admda7 with agents commonly used to treat breast cancer: radiotherapy (XRT), Tamoxifen, Taxotere, Adriamycin, and Herceptin. These agents exhibit diverse modes of action, including formation of bulky adducts, inhibition of DNA replication (Adriamycin, XRT), damage to microtubules (Taxotere), nonsteroidal estrogen antagonists (Tamoxifen), or Her2/neu receptor blockade (Herceptin). Treated with conventional anticancer drugs or radiation, MDA-7-expressing cells display additive or synergistic cytotoxicity and apoptosis that correlates with decreased BCL-2 expression and BAX upregulation. In vivo, animals that received Ad-mda7 and XRT underwent significant reduction of tumor growth (Po0.002). This is the first report of the synergistic effects of Ad-mda7 combined with chemotherapy or radiotherapy on human breast carcinoma cells.
Introduction
Breast cancer is the most common type of cancer among women in the United States, ranking second in cancerrelated deaths, after lung cancer. Even though the death rates for breast cancer patients have improved due to better therapies and earlier detection, there are still three million women affected in America today, and the disease caused more than 39 000 deaths in 2003. Treatment of breast cancer involves a combination of therapies including surgery, radiation therapy (XRT), and hormone therapy or chemotherapy. The most commonly utilized chemotherapeutic agents for breast cancer include Adriamycin-based regimens with or without the addition of taxanes. [1] [2] [3] [4] Hormonal agents, including Tamoxifen and aromatase inhibitors, 2, 5 and biologic therapies are now used in the management of metastatic breast cancer. Herceptin, which can be used as a single agent or in combination with chemotherapy, has been approved for patients with tumors that overexpress Her-2/neu. 6 These agents have very different modes of action and intracellular targets.
Tamoxifen, used for over 20 years to treat patients with hormone receptor positive breast cancer, works against the effects of estrogen on breast cancer cells. 1, 2 Herceptin, a humanized antibody targeting the human epidermal growth factor receptor-2 (Her-2/neu), blocks activity of this proto-oncogene. 1, 6 Taxotere 3 is an anticancer drug that disrupts the microtubule network, and was the first anticancer agent to show a response rate superior to that of doxorubicin (Adriamycin), which is widely used in the adjuvant and neoadjuvant setting for breast cancer treatment. Adriamycin was the first single agent to demonstrate increased survival among patients with advanced breast cancer when compared to combination chemotherapy. 4 This agent is thought to prevent DNA replication and act as a topoisomerase inhibitor, although the exact mechanism by which Adriamycin exerts its actions is still being studied. 4, 5 A major problem in the treatment of cancers is tumor cells' acquisition of resistance to chemotherapeutic agents; thus, there is increased interest in finding new agents for molecular-targeted therapies. [6] [7] [8] [9] Novel approaches using replication-defective adenoviral vectors encoding tumor suppressor genes, such as the melanoma differentiation associated gene 7 (mda-7), 10 are gaining popularity. Several groups have demonstrated that adenoviral mediated overexpression of mda-7 (Ad-mda7) induces apoptosis in a wide range of cancer cells. [11] [12] [13] [14] In spite of its clear tumor suppressive effects, the mechanisms by which Ad-mda7 induces cytotoxicity have not been fully characterized. MDA-7 activates various signaling pathways in different tumor cell types; [15] [16] [17] [18] [19] [20] [21] [22] [23] these pathways ultimately converge on mitochondrial destruction resulting in apoptosis induction.
Here, we demonstrate that Ad-mda7, as a single agent therapy, potently induces apoptosis and inhibits growth in a panel of nine breast tumor cell lines in a p53-independent manner. Furthermore, MDA-7 expression significantly enhances the cytotoxic response of breast tumor cells to chemotherapeutic agents, in spite of their diverse mechanisms of action. We also investigated the effects of MDA-7 expression in the response of breast cancer cells to radiotherapy. We demonstrate that mda-7 gene expression and XRT are synergistic, and the combination of Ad-mda7 and XRT therapy results in decreased breast cancer cell survival in vitro and in vivo. This is the first report demonstrating the synergistic effects of Ad-mda7 when combined with chemotherapeutic agents or XRT in human breast carcinoma cells. Using Ad-mda7 in conjunction with treatments currently used in the clinic may allow enhanced killing of breast carcinoma cells with lower toxicity than standard doses of either agent alone.
Materials and methods

Cells and reagents
Breast cancer cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD). The breast cancer cell lines evaluated were T47D, MCF-7, MDA-MB-453, SKBr3, MDA-MB-231, MDA-MB-468, MDA-MB-361, HBL-100 and BT-20. Primary human mammary epithelial cells (HMEC), human vascular endothelial cells (HUVEC) and MJ-90 human fibroblasts were obtained from Clonetics (San Diego, CA). The cells were grown in DMEM medium (GIBCO, Grand Island, NY) and fetal bovine serum (5-10%, according to each cell line), and routinely tested for mycoplasma. Herceptin (Genentech, San Francisco, CA), Taxotere (Aventis-RPR, Collegeville, PA), Tamoxifen (Sigma-Aldrich, St Louis, MO), and Adriamycin (Adria Labs, Columbus, OH) were obtained from the MD Anderson Cancer Center pharmacy.
Recombinant adenovirus
Production of the replication-deficient human type 5 Adenovirus (Ad5) containing the mda-7 gene (Ad-mda7), luciferase reporter gene (Ad-luc) or empty vector (AdCMVp(A)) have been previously reported. 11 Construction of Ad-mda7 involved linking mda-7 cDNA to a CMV-IE promoter, followed by an SV40 polyadenylation [p(A)] sequence; this expression cassette was placed in the E1 region of Ad5. PCR, restriction endonuclease digestion, and DNA sequencing analyses were used to verify virus stocks.
Western blot analysis
Cell lysates were subjected to 10% SDS polyacrylamide gel electrophoresis and analyzed by Western blot, using the Super-Signal substrate for Horse-Radish Peroxidase (Pierce, Inc.). Polyclonal and monoclonal antibodies against MDA-7 were produced by Introgen Therapeutics. Other monoclonal antibodies used in the study recognized PKR, p53, BCL-2, BCL-XL, BAX, a-tubulin and b-actin (Santa Cruz Biotechnology). Secondary antibodies were purchased from Santa-Cruz Biotechnology (Santa Cruz, CA) and from Amersham Biosciences (Piscataway, NJ).
Transduction and drug treatments
Cells were transduced with Ad-mda7, Ad-empty or Ad-luc with increasing multiplicities of infection (MOIs) in the presence or absence of the drugs as indicated (Tamoxifen 1-10 mg/ml; Taxotere 1-10 ng/ml; Adriamycin 1-10 ng/ml and Herceptin 1 mg/ml). Cells were plated at 500-2000 cells/well in 96-well format for 3 H-labeled Thymidine incorporation assays, or at 10 5 -10 6 cells/well in a six-well plate format for protein expression, Trypan blue viability or apoptosis assays. In drug combination studies, drugs were added once just prior to addition of vectors and cells were continuously exposed to agents.
Cell proliferation analyses
Growth inhibition of cells was measured by 3 H-labeled Thymidine incorporation into actively replicating cells' DNA. 3 H-labeled Thymidine was added to the cells (1 mCi/ml) and the reaction stopped 15 h later by removal of the supernatant from recipient cells. The cells were harvested using Trypsin/EDTA (GIBCO), collected on a Filter using a Packard Filtermate cell Harvester, and washed in deionized water and methanol following the manufacturer protocols. The filters were dried and analyzed using a Matrix 9600 (Packard).
Apoptosis and cell viability assays Apoptosis was measured by TUNEL and Annexin V assays. For TUNEL assays, tumor sections were analyzed for apoptosis using the Chromogenic TUNEL-POD (Roche Diagnostics, Indianapolis, IN) assay following the manufacturer's protocols, 13 and TUNEL positive cells identified by their dark brown staining. Annexin V assays were carried out using the ApoAlert Annexin V-FITC kit (CLONTECH, Palo Alto, CA). 11 Cell viability was determined by Trypan-blue exclusion assay.
Cell cycle analysis with propidium iodide (PI) staining. Cell-cycle progression was determined by PI staining of cellular DNA. Cells were prepared as a single-cell suspension of 1-2 Â 10 6 cells/ml of PBS, fixed with cold 70% ethanol for 2 h, and centrifuged. The fixative was decanted, and the cells washed in PBS, and stained with PI (50 mg/ml) and RNAse (20 mg/ml in PBS). Treated cells were evaluated by FACS analysis.
Clonogenic survival assays. Clonogenic survival assays were performed using Ad-mda7 and Ad-CMVp(A) (MOI 2000 viral particles/cell) in combination with XRT (0, 2 or 4 Gy). MDA-MB-468 breast cancer cells were cultured at 1 Â 10 5 cells with empty adenovirus vector (Ad-CMVp(A)) or Ad-mda7 for 2 days and then treated with XRT. Cells were reseeded at a density of 2.5 Â 10 5 cells. Clonogenic survival was assessed 3 weeks later; colonies were fixed, stained with Giemsa, and counted. 18 Animal studies and immunohistochemical analysis Balb C nu/nu mice were obtained from Charles River Laboratories (Wilmington, MA). Female mice (6 weeks old) were injected with breast cancer cells into the right hind limb and observed for tumor growth. In all the experiments, tumor cells (MDA-MB-361; MCF-7 or MDA-MB-468) suspended in 100 ml sterile phosphatebuffered saline (PBS) were injected into the right dorsal flank and allowed to grow to approximately 100 mm 3 . Animals were then randomized into groups (n ¼ 5-10 animals/group) and treatment initiated as follows: Group 1 received PBS, Group 2 received Ad-Luc and Group 3 received Ad-mda7. Dosing schedules varied for different models: in the MB-361 xenograft model, when tumors reached 130 mm 3 , 10 animals per group were injected with PBS, Ad-luc or Ad-mda7 at doses of 1 Â 10 10 vp on alternate days for a total of three doses. In the MDA-MB-468 model, five animals each with tumors of 130 mm 3 were injected with PBS, Ad-luc or Ad-mda7 at a dose of 2 Â 10 10 vp on alternate days for a total of three injections. In MCF-7 xenograft models, 10 animals per group were injected when tumors reached 85 mm 3 with PBS, Ad-luc or Ad-mda7 at 1 Â 10 10 , 3Â 10 10 or 1 Â 10 11 vp on alternate days for six injections.
For evaluation of radiotherapy combinations, mice were divided into six treatment groups (n ¼ 5 per group): PBS, Ad-luc, Ad-luc þ XRT, XRT alone, Ad-mda7, Admda7 þ XRT. The tumors were treated by direct injection with PBS or adenoviral vectors at a dose of 2 Â 10 10 vp/ml on days 1, 3 and 5. On day 6, the animals were treated with a single application of radiation (5 Gy) to the hind limb. Tumor measurements were taken every other day and the volume was calculated. The tumors were harvested from selected mice and embedded in paraffin immediately after the animals were killed. Tumor samples were analyzed for MDA-7 and PKR expression by immunohistochemistry using the BCIP/NBT substrate kit (Vector Laboratories, Burlingame, CA). Intratumoral injections were performed under anesthesia using methoxyflurane (Schering Plough, Kenilworth, NJ) as per institutional guidelines. Tumor measurements were recorded every other day without knowledge of the treatment groups, and the volume was calculated using the formula
, where a is the largest dimension and b is the perpendicular diameter. 15, 23 Mice were euthanized when the tumors reached 1.5 cm in size.
Statistical analysis
The statistical significance of the experimental results was calculated using Student's t-test for tumor measurements. ANOVA and two-tailed Student's t-test were used for statistical analysis of multiple groups and pairwise comparison, respectively, with Po0.05 considered significant. MDA-7 expression inhibited cell proliferation by up to 96%, while growth of Ad-luc-transduced cells was minimally altered. These results suggested that Ad-mda7 might induce cell cycle arrest, and thus we performed cell cycle analysis (PI staining) of untreated, Ad-luc and Ad-mda7 transduced MDA-MB-453 and MCF-7 cells. As shown in Figure 1c , cells transduced with Ad-mda7 undergo cell cycle block, and a two-to three-fold increase in the fraction of G2/M cells compared to untreated or Ad-luc treated cells.
Results
MDA
The kinetics and dose-response of cell death were evaluated, and representative data are shown for MDA-MB-453 cells (Figure 1d ): at low Ad-mda7 doses (1000 vp/cell: 50 PFU/cell), significant cell death (Po0.001) was observed at 2 days post-treatment; at higher doses significant killing was observed at day 1, and increased with time. In sum, MDA-7 expression kills breast tumor cells in both a time-and dose-dependent manner, whereas Ad-luc shows only minor effects (Figure 1d ). In contrast, the corresponding normal cells, HMEC show no significant toxicity from Ad-luc and Ad-mda7, even at longer time points (Figure 1e ). Additional studies using normal fibroblasts and primary endothelial cells confirmed the lack of cytotoxicity against normal cells (Table 1) .
Apoptosis induction by Ad-mda7
The expression of MDA-7 in tumor cells may affect signals other than those related to inhibition of cell growth, and is reported to activate apoptotic pathways in various cancer cell types. [11] [12] [13] [14] In agreement with these findings, we observed that transduction with Ad-mda7 triggers apoptosis in T47D, MCF-7, MDA-MB-453 and MDA-MB-468 cell lines (41, 52, 43 and 32% respectively) ( Figure 2a ). In contrast, when these lines were transduced with control Ad-luc or Ad-empty, the number of cells undergoing apoptosis was comparable to that observed in vehicle-treated cells. Further assays on these cell lines confirmed that Ad-mda7 induced apoptosis dosedependently (data not shown), and upregulated BAX in T47D breast cancer cells (Figure 2b ). Treatment with the pan-caspase inhibitor ZVAD reduced apoptosis by 40%; however, MDA-7 induction of BAX was not reduced. Treatment with Ad-luc did not activate BAX or apoptosis ( Figure 2b ). The mechanism of apoptosis induction was then evaluated. Ad-mda7 induced cleavage of caspase 3 and PARP, consistent with mitochondrial-mediated apoptosis induction (Figure 2c ).
Expression of mda-7 reduces tumor growth in vivo
To determine if the in vitro growth inhibition of breast cancer cells induced by Ad-mda7 translated into a similar effect on tumor growth in vivo, we evaluated xenograft tumors generated using MDA-MB-361, MDA-MB-468 and MCF-7 cells in nude mouse models. When the tumors reached approximately 100 mm 3 , the animals were divided into treatment groups (n ¼ 5-10 animals per group), and treated with PBS, Ad-luc or Ad-mda7. As shown in Figure 3 , direct injection of the tumors with Ad-mda7 induced significant reduction of tumor volume, evident by day 10, on all three xenograft models (P ¼ 0.002-0.004). By day 20, control tumors treated with Ad-luc or PBS had undergone a four-to eight-fold increase in volume, reaching a maximum of greater than 800 mm 3 . In contrast, Ad-mda7 treated tumors showed either minor tumor growth (MDA-MB-361 and MDA-MB-468) or grew to approximately three-fold their initial volume (MCF-7). Ad-luc induced a variable effect on tumor growth, with maximal effect in the MB-361 model; however, Ad-mda7 consistently induced much more robust and stable growth inhibition and resulted in prolonged tumor growth control in all three models. Significant growth inhibition was evident in both tumor cells that were mutant and wild type for p53 (see Table 2 ). We performed a dose-escalation study in p53 wild-type MCF-7 tumors and found that low doses were not effective at blocking tumor growth, whereas a three-fold higher dose produced some tumor growth inhibition (P ¼ 0.08) and a log higher dose produced robust tumor growth inhibition of this aggressive tumor (P ¼ 0.002) ( Table 2 and Figure 3 ). The rate of tumor growth was 
significantly reduced by Ad-mda7 treatment (see Figure 3) , as reflected in the time required for these tumors to double in size (Table 2 ). These results show that expression of MDA-7 has antiproliferative activity both in vitro and in vivo, in both p53 wild type and p53 mutant breast cancer cells. MDA-MB-468 xenografts were also analyzed for MDA-7 expression and apoptosis induction. Strong MDA-7 immunostaining was observed in Ad-mda7 treated, but not in PBS or Ad-luc treated tumors (Figure 3d ). TUNEL analysis showed that MDA-7 protein expression correlated with apoptosis. MDA-7 expressing tumors showed high expression of PKR protein (Figure 3d ), similar to that observed in vitro (Figure 1a) .
Combination of Ad-mda7 transduction with Tamoxifen, Taxotere or Adriamycin treatments has an additive effect on breast tumor cell death As shown above, single-agent therapy with Ad-mda7 exhibits promising antitumor activity against breast cancer cells. However, current treatments for breast cancer employ a multimodality therapeutic approach combining cytotoxic chemotherapies, XRT, hormonal therapy and new biologic therapies, such as Herceptin. [1] [2] [3] [4] [5] [6] To investigate if combining Ad-mda7 with chemotherapeutic agents could enhance cytotoxicity, breast cancer cell lines were treated with Ad-mda7 and a series of chemotherapeutic agents, and analyzed using cell proliferation and cell viability assays. We first treated these cells with the estrogen antagonist Tamoxifen, a nonsteroidal agent that acts by competing with estrogen for binding of its receptors in target tissue. 1, 2 To facilitate evaluation of combinatorial drug interactions, we used subtherapeutic doses of each agent.
We established a dose-response between Ad-mda7 and Tamoxifen (Figure 4a ). Low doses of Ad-empty (0-1000 vp/cell) or Tamoxifen (up to 2 mg/ml) reduced cell proliferation by less than 20% in T47D cells. Addition of Ad-mda7 at very low doses (100 vp/cell) did not affect cell growth while 500 vp/cell and 1000 vp/cell of Ad-mda7 resulted in dose-dependent growth inhibition when combined with Tamoxifen (60 and 80% inhibition, respectively). As shown in Figure 4b (top panel), MCF-7 cells showed a minor response (o15%) to Tamoxifen (1 mg/ml) and Ad-mda7 (at 1000 vp/cell) alone, but treatment with a combination of both agents had a synergistic effect and reduced cell proliferation by more than 60% (Po0.001). We further evaluated p53 mutant T47D cells: in this case, treatment with Ad-mda7 as a single agent significantly reduced growth. However, as was the case with p53 wild-type MCF-7 cells, the effect of the two combined therapies was synergistic, and reduced thymidine counts by 80% (Po0.01). Transduction of tumor cells with Ad-luc or Ad-empty reduced growth by p15%. A similar synergistic interaction was also observed in MDA-MB-361 cells (data not shown).
To investigate if Ad-mda7 could enhance the effects of agents that belong to the taxane family, we treated breast cancer cells with Taxotere (docetaxel, 0.5-2 ng/ml). Taxotere is an antineoplastic drug that disrupts the microtubule network, and prevents cells from completing mitosis and interphase. [1] [2] [3] We performed cell growth assays on T47D and MCF-7 with doses of Taxotere that result in approximately 40% inhibition of Thymidine incorporation (Figure 5a, b) . The cells were sensitive to Ad-mda7 but not Ad-luc; when Ad-mda7 was combined with Taxotere, enhanced sensitization was observed in both cell lines. Identical results were obtained in MDA-MB-361 cells (data not shown). We then tested Adriamycin (doxorubicin), a cytotoxic anthracycline antibiotic, whose effects are thought to be mediated by its nucleotide base intercalation and cell membrane lipid 1 ng/ml Adriamycin resulted in minor (17-23%) reduction in cell growth, but the combination of both agents resulted in significantly greater (460%) growth inhibition (Po0.01). We then evaluated apoptosis signaling (p53; BCL-XL; BCL-2 and BAX) in breast cancer cells treated with Ad-mda7 in combination with Taxotere, Adriamycin, Tamoxifen and Herceptin (Figure 6c and Table 3 ). Singleagent Ad-mda7 treatment of breast tumor cells did not substantially alter steady-state levels of p53 or BCL-XL, while it decreased expression of BCL-2 and upregulated BAX (Figure 6c) , similar to the effect observed in T47D cells. In cells treated with Taxotere, Adriamycin or Herceptin, no significant alterations in p53 and BCL-XL were noted after Ad-mda7 treatment (Table 3) . Steadystate levels of BCL-2 and BCL-XL were reduced in cells treated with both chemotherapies. Ad-mda7 induced upregulation of BAX in cells treated with Taxotere or Adriamycin, whereas MDA-7 expression caused decreases in BCL-2 when combined with Herceptin (Figure 6c ). The molecular changes in p53 and BCL-2 family members are summarized in Table 3 . These apoptotic mediators demonstrate differential regulation based upon the drug and vector used. Ad-mda7 consistently upregulated BAX in breast cancer cells when delivered either as monotherapy or in combination with chemotherapies.
Herceptin is a humanized antibody developed as an antagonist for the human epidermal growth factor receptor-2 (HER-2). 6 In this study, we evaluated whether cytotoxicity of Herceptin on MDA-MB-453 (HER2 overexpressing) and MCF-7 (HER2 negative) cells was enhanced by expression of Ad-mda7 (Figure 6d ). Indeed, we observed a synergistic 45-fold increase in cell death of MDA-MB-453 cells compared to untreated controls, when cells were transduced with Ad-mda7 combined with Herceptin (Po0.001). In contrast, MCF-7 cells were Adenoviral mda-7 sensitizes breast cancer cells to chemotherapy and radiation S Chada et al resistant to Herceptin, as predicted by their lack of Her-2 receptor expression. Ad-mda7 induced death in MCF-7 cells; however, the combination of Ad-mda7/Herceptin did not show enhanced activity. Treatment with Ad-luc either as a single agent or in combination with Herceptin, under similar conditions as above, did not significantly increase the percentage of cell death observed. These results indicate that the combined use of Ad-mda7 and chemotherapeutic, hormonal or biologic agents can lower the treatment concentrations required for tumor cell death compared to monotherapy treatment, and thus potentially reduce the associated toxicities.
Combination of Ad-mda7 with XRT has a synergistic effect on breast cancer cells clonogenic survival and tumor growth We then investigated the impact of Ad-mda7 and XRT combination therapy on MDA-MB-468 breast cancer cells. MDA-MB-468 cells were treated with an empty adenoviral vector (Ad-p(A)) or Ad-mda7 (both at a MOI of 2000 vp/cell), and irradiated. Antitumor activity was evaluated using a colony formation assay. As shown in Figure 7a , we observed a significant decrease in survival of the Ad-mda7 þ XRT treated cells compared to XRT or Ad-p(A). MDA-7 mediated enhancement of tumor cell killing was observed at both 2 and 4 Gy XRT (Figure 7a ). These results show that the combination of Ad-mda7 þ XRT inhibits colony formation in MDA-MB-468 cells, in vitro, in a supra-additive manner.
To investigate the effects of the combined Ad-mda7 and XRT therapy, in vivo, we treated large (4130 mm 3 ) MDA-MB-468 breast cancer xenograft tumors with Ad-mda7, Ad-luc or PBS individually or combined with XRT (5 Gy) The animals were divided into six treatment groups (n ¼ 5 in each group), and treated with PBS, Adluc, Ad-luc þ XRT, XRT, Ad-mda7 or Ad-mda7 þ XRT. Marked differences in tumor size between the treatment groups were evident within 1 week after treatment cessation. Treatment with XRT alone, Ad-mda7 alone, and the combination of Ad-luc and XRT all resulted in significant decreases in tumor growth (Po0.05). However, the most marked change was seen in the animals that received the combination of XRT and Ad-mda7. As shown in Figure 7b , we noted a substantial inhibition of tumor progression in the Ad-mda7-treated animals; however, regression in tumor growth was observed when Ad-mda7 and XRT were used in combination (P ¼ 0.0017). Tumors from Ad-mda7/XRT treated animals initially increased in size by approximately 50%, but subsequently regressed by up to 80%. All of the animals Control tumors increased in size by more than 500%, whereas XRT treated tumors increased by 4350%. Tumors in the Ad-mda7/XRT group exhibited prolonged stabilization, whereas the XRT, Ad-luc or Ad-luc/XRT tumors grew progressively larger. When evaluated for time to tumor size doubling, PBS and Ad-luc treated animals reached this size by days 10 and 11, respectively; animals in both XRT and Ad-luc/XRT groups took 16 days whereas Ad-mda7 treated tumors took 25 days. Tumors from Ad-mda7/XRT treated animals had not doubled in size by 430 days, and averaged 25% smaller than their starting size. We observed elevated expression of transgenic MDA-7 protein only in Ad-mda7-treated tumors, but not in PBS-or Ad-luc-treated tumors (Figure 3d ).
Discussion
Current breast cancer therapies are aimed at achieving regional control at the tumor site with surgery and XRT, and at controlling systemic disease with chemotherapy and hormonal therapy. Patients are treated using multimodality therapy on the basis of disease stage. [1] [2] [3] [4] 6 However, patients within each stage grouping demonstrate divergent responses to treatment and widely different overall outcomes. It is clear that new treatment paradigms are required to facilitate tailoring of protocols to individual patients, based on improved understanding of the molecular features of breast cancer relevant for prognosis and response. 7, 21, 24 The rational design of future clinical trials will require an understanding of drug interactions at the molecular and cellular levels to allow for optimal scheduling, dosing and clinical utility.
At the cellular level, current therapeutic approaches face another challenge in the heterogeneous nature of the primary tumor population. This leads to multifactorial drug resistance, and allows therapy-resistant cells to survive and proliferate. Multiple cell survival pathways are activated by tumor cells in vivo, and may cooperate to promote drug resistance, for example by upregulation of MDR drug transporter proteins. Alterations in programmed cell death (apoptosis) pathways is another mechanism by which cancer cells develop a survival advantage, leading to uncontrolled proliferation and resistance to chemotherapy and radiotherapy. 8, 9 Thus, 
Cell lysates were immunoblotted using antibodies against p53, BCL-2, BCL-XL, BAX and normalized using tubulin. Signals in Ad-mda7 lysates were compared to the corresponding Ad-luc treatment. k: decreased expression compared to Ad-luc control; m: increased expression compared to Ad-luc control; -: no change between Ad-mda7 or Ad-luc; NS: no signal. 3 , animals were divided into six treatment groups (n ¼ 5 animals in each group): PBS, Ad-luc, Ad-luc þ XRT, XRT, Ad-mda7 and Ad-mda7 þ XRT. Recombinant adenoviruses were delivered by intratumoral injection at a dose of 2 Â 10 10 vp/ml every other day for a total of three injections. At 24 h after the third injection, a single dose of 5 Gy was delivered to the hind limb. Tumors were assessed for growth by measurements in two dimensions and tumor volume was recorded. There was a marked difference in tumor size between the treatment groups. Ad-mda7 monotherapy produced greater tumor growth inhibition than XRT alone or Ad-luc/XRT. The most marked growth suppression was seen in the animals that received the combination of XRT and Ad-mda7. *Po0.002.
Adenoviral mda-7 sensitizes breast cancer cells to chemotherapy and radiation S Chada et al effective long-term strategies for breast cancer treatment, with novel agents that regulate both cell survival and apoptotic pathways, alone or in combination with standard antitumor regimens, are required.
The recently identified mda-7 gene exhibits significant antitumor activity in a variety of malignant cell lines. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] This study expands upon previous reports where breast tumor lines were treated with Ad-mda7 as monotherapy. 11, 12 We document potent antitumor activity of Ad-mda7 as monotherapy against breast cancer cell lines harboring varying mutations in p53, ER and Her2/neu, and we have gathered evidence that MDA-7 can enhance the apoptotic effects of Herceptin directly and indirectly (bystander effect) in breast cancer cells (in preparation). We also observed significant antitumor activity in p53 wild type and p53 mutant breast cancer xenografts in vivo. The mechanism by which Ad-mda7 induces apoptosis, however, seems to involve various cell type-dependent signaling pathways and has not been entirely defined. [13] [14] [15] [16] [17] [18] [19] [20] While some authors report increases in proapoptotic proteins such as p53, BAX and BAK following Ad-mda7 transduction, [11] [12] [13] 16 others observe regulation of different signaling molecules, such as Fas, TRAIL, PKR, b-catenin, PI3K, MAPK and others. 15, [17] [18] [19] [20] [21] [22] [23] These studies, however, have been largely correlative and have not defined which upstream genes are required for caspase activation and apoptosis. In lung cancer cells, mda-7 gene expression induces upregulation of PKR, 19 known to be involved in the host interferon-induced antiviral response and a potent effector of apoptosis. 25, 26 Here, we present the first evidence for in vivo regulation of PKR following treatment of breast cancer tumors with Ad-mda7, and suggest this relationship is not linked to a particular cell type, but rather part of a more general MDA-7-induced mechanism. Upregulation of PKR was specific for Ad-mda7 since no significant changes in PKR level or activity were seen following treatment of breast cancer cells with Ad-luc or Ad-empty. Previously, we noted that treatment of lung cancer cells with 2-aminopurine (2-AP), a serine/threonine kinase inhibitor, inhibited Ad-mda7-induced PKR activation and apoptosis induction. 19 In addition, PKR-null fibroblasts but not wild-type fibroblasts were resistant to Ad-mda7-induced apoptosis. 19 These results suggested that PKR plays a key role in Ad-mda7-induced apoptosis in lung cancer cells, and may also be a critical mediator of apoptosis in breast cancer cells. We have now demonstrated that MDA-7 directly binds PKR in lung cancer cells, thus identifying the first binding partner for MDA-7. 27 We demonstrated that MDA-7 is phosphorylated on serine and threonine, but not on tyrosine residues. 11, 27 Phosphorylation of MDA-7 correlates with its cytotoxicity. 27 Thus, the accumulated data indicate that PKR may be the kinase responsible for directly phosphorylating MDA-7 and mediating apoptosis in lung and potentially, breast tumor cells.
This preclinical study documents quantitative interactions between Ad-mda7 and different chemotherapeutics representing four classes of cytotoxic anticancer drugs in addition to radiotherapy. The drugs tested: Tamoxifen, Taxotere, Adriamycin and Herceptin induce death of breast cancer cells via different and non-cross-resistant (overlapping) mechanisms. These studies were conducted using multiple breast cancer cell lines independently characterized for p53 mutational status, demonstrating that the observed results are not cell line specific or p53 dependent. Supra-additive and synergistic anticancer activity was found using low doses of Ad-mda7 and conventional drugs -in general, drug doses less than the IC 20 were used; the doses of chemotherapeutics used in this study are easily achievable in the clinic. For example, peak plasma concentrations for Taxotere, Adriamycin, Tamoxifen and Herceptin have been reported as 3.6, 5.6, 0.4 and 0.8 mM, respectively. 1, 6 The drug levels, which demonstrated synergistic interaction with Ad-mda7, were much lower than the doses used in humans; for example, synergistic activity was observed with Taxotere and Adriamycin at levels 1000-fold lower than peak plasma levels in humans, whereas Herceptin levels were 4100-fold lower.
Chemotherapeutic and biologic agents exert antitumor responses through various mechanisms of action. Thus, the use of therapeutic agents with non-cross-resistant (nonoverlapping), complementary or ideally, synergistic cytotoxic mechanisms may enable improvements in efficacy without eliciting additive toxicities. Clinically, chemotherapeutic drugs are used at their maximum tolerated dose (MTD). The goal of development of molecularly targeted agents is to identify drug combinations that provide synergistic anticancer activity via nonoverlapping mechanisms without increasing toxicity to normal tissue or acquisition of cross-resistance. Based on the spectrum of synergistic activities of Ad-mda7 when delivered in combination with chemotherapy, biologic therapy and radiotherapy, mda-7 gene delivery may offer promise to patients with breast cancer. Further, the low doses of chemotherapy and biologic therapy required for synergy with Ad-mda7 may translate into reduced toxicity in patients.
MDA-7 activates common downstream apoptotic effector proteins such as BAX ( Figures 2 and 6c) ; elevation of BAX and induction of apoptosis were observed in multiple p53 mutant breast cancer cell lines (T47D, MDA-MB-453, MDA-MB-468) in addition to p53 wild-type lung cancer cells (A549) (Figures 2b, c and  6c ). When Ad-mda7 was combined with Taxotere or Adriamycin in breast cancer cells, BAX upregulation was consistently observed and was p53-independent. Our results are in agreement with reports that correlate induction of apoptosis with changes in the balance between pro-and antiapoptotic proteins of the BCL-2 family. [11] [12] [13] Regulation of BAX expression appears to be important in development of breast cancer and downregulation of BAX correlates with drug resistance in breast cancer. 28 A recent study evaluated regulation of BCL-2 family members and caspases in response to chemotherapy in 35 patients with breast cancer. Tumors were excised 24 h after chemotherapy and immunohistochemistry of BCL-2, BAX, XIAP, activated (cleaved) caspase 3 and 6, and cleaved DNA Fragmentation Factor-40 (DFF40) were compared in pre-and post-treatment biopsies. BAX was the only BCL-2 family member that correlated with increased apoptosis in breast tumors after chemotherapy. 29 We have completed a phase I clinical trial evaluating Ad-mda7 (INGN 241) in patients with advanced cancers. 30, 31 Four patients with metastatic breast cancer were treated: these patients had demonstrated tumor recurrence after multiple treatments, including surgery, Tamoxifen, Taxotere, Cyclophosphamide and Herceptin. 31 In all cases, Ad-mda7 treatment resulted in high levels of ectopic MDA-7 expression that correlated with substantial TUNEL reactivity (up to 65% apoptosis in the center of the tumor). These recurrent human tumors would be predicted to be resistant to apoptosis; however, all were able to activate apoptosis pathways in response to MDA-7 expression. 30 Thus, Ad-mda7 can induce high levels of apoptosis in breast cancer cell lines in vitro and in vivo in xenograft models in addition to heavily pretreated recurrent tumors in patients. In vivo, Ad-mda7 demonstrates enhanced activity when combined with Herceptin. 21 A recent study also demonstrated combinatorial synergy in vitro and in vivo when Ad-mda7 was combined with the chemotherapeutic sulindac in lung cancer cells. 32 The enhanced activity was due to regulation of MDA-7 protein turnover, resulting in an increase in half-life of MDA-7 protein. 32 In lung cancer models, Ad-mda7 demonstrated synergy with radiotherapy that appears to be mediated by inhibition of DNA repair and potent antiangiogenic effects in vivo. 18, 33 Radiosensitization has also been observed in glioma models. 34, 35 Activation of cell stress pathways correlates with upregulation of endogenous mda-7 gene expression and cell death in glioblastoma and medulloblastoma models. 36 These pathways are also activated in melanoma (Kokkinakis and Chada, unpublished data). Both Ad-mda7 and MDA-7 protein activate cell stress pathways in tumor cells that may promote combinatorial synergy with chemotherapy and radiotherapy. 17, 22, 37, 38 Additional functions of mda-7 that may aid in breast cancer treatment are inhibition of cell invasion and metastasis 17, 39, 40 and potential for immune activation. 41 In summary, we show that expression of MDA-7 results in growth suppression, cell cycle arrest, and increased sensitivity of breast cancer cells to multiple cytotoxic agents, in spite of their diverse mechanisms of action. We demonstrate combinatorial synergy of Ad-mda7 and XRT in a breast tumor xenograft model compared to the use of either treatment alone. We expect these results will provide a foundation for further development of Ad-mda7 as a potential therapeutic agent in the treatment of breast cancer.
